{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:59:34Z","timestamp":1793714374668,"version":"4.6.1"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":434,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence of invasive fungal infections is increasing in immune-competent and immune-compromised patients. An examination of the recent literature related to the treatment of fungal infections was performed to address two clinical questions. First, in patients with proven or probable invasive pulmonary aspergillosis, should combination therapy with a mold-active triazole plus echinocandin be administered versus mold-active triazole monotherapy? Second, in critically ill patients at risk for invasive candidiasis who are nonneutropenic and are not transplant recipients, should systemic antifungal agents be administered either as prophylaxis or as empiric therapy?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multidisciplinary panel reviewed the available data concerning the two questions. The evidence was evaluated, and recommendations were generated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A conditional recommendation was made for patients with proven or probable invasive pulmonary aspergillosis to receive either initial combination therapy with a mold-active triazole plus an echinocandin or initial mold-active triazole monotherapy, based on low-quality evidence. Furthermore, a conditional weak recommendation was made against routine administration of prophylactic or empiric antifungal agents targeting Candida species for critically ill patients without neutropenia or a history of transplant, based on low-quality evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The recommendations presented in these guidelines are the result of an analysis of currently available evidence. Additional research and new clinical data will prompt an update in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202410-2045st","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T11:30:46Z","timestamp":1731929446000},"page":"34-53","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":41,"title":["Treatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients: An Official American Thoracic Society Clinical Practice Guideline"],"prefix":"10.1093","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6920-0540","authenticated-orcid":false,"given":"Oleg","family":"Epelbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-787X","authenticated-orcid":false,"given":"Tina","family":"Marinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qusay","family":"Haydour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1187-5059","authenticated-orcid":false,"given":"Kelly M.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4503-0644","authenticated-orcid":false,"given":"Scott E.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5261-6558","authenticated-orcid":false,"given":"Kenneth S.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Jarrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Meyer-Zilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hassan","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5671-6874","authenticated-orcid":false,"given":"Andrew H.","family":"Limper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0582-4362","authenticated-orcid":false,"given":"Chadi A.","family":"Hage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,1]]},"reference":[{"key":"2026031105194334400_bib1","doi-asserted-by":"crossref","first-page":"ofy187","DOI":"10.1093\/ofid\/ofy187","article-title":"Epidemiology and clinical features of invasive fungal infection in a US health care network","volume":"5","author":"Webb","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2026031105194334400_bib2","doi-asserted-by":"crossref","first-page":"108731","DOI":"10.1016\/j.clim.2021.108731","article-title":"Invasive fungal disease and the immunocompromised host including allogeneic hematopoietic cell transplant recipients: improved understanding and new strategic approach with sargramostim","volume":"228","author":"Chu","year":"2021","journal-title":"Clin Immunol"},{"key":"2026031105194334400_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.tim.2020.01.009","article-title":"AIDS-related mycoses: updated progress and future priorities","volume":"28","author":"Hoving","year":"2020","journal-title":"Trends Microbiol"},{"key":"2026031105194334400_bib4","doi-asserted-by":"crossref","first-page":"ofab593","DOI":"10.1093\/ofid\/ofab593","article-title":"Prevalence and healthcare burden of fungal infections in the United States, 2018","volume":"9","author":"Rayens","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026031105194334400_bib5","doi-asserted-by":"crossref","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci Transl Med"},{"key":"2026031105194334400_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105194334400_bib7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Schunemann","year":"2008","journal-title":"BMJ"},{"key":"2026031105194334400_bib8","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"2026031105194334400_bib9","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1086\/517849","article-title":"Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality\u2014SEIFEM-C Report","volume":"44","author":"Pagano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2026031105194334400_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.idc.2021.03.008","article-title":"Aspergillosis: epidemiology, diagnosis, and treatment","volume":"35","author":"Cadena","year":"2021","journal-title":"Infect Dis Clin North Am"},{"key":"2026031105194334400_bib12","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1128\/AAC.46.9.3039-3041.2002","article-title":"In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp","volume":"46","author":"Perea","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105194334400_bib13","doi-asserted-by":"crossref","first-page":"e00305-17","DOI":"10.1128\/AAC.00305-17","article-title":"Combination therapy with isavuconazole and micafungin for treatment of experimental invasive pulmonary aspergillosis","volume":"61","author":"Petraitis","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105194334400_bib14","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1128\/AAC.01556-08","article-title":"Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin","volume":"53","author":"van de Sande","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105194334400_bib15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib16","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study","volume":"95","author":"Pagano","year":"2010","journal-title":"Haematologica"},{"key":"2026031105194334400_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2014.08.012","article-title":"Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies","volume":"45","author":"Raad","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2026031105194334400_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026031105194334400_bib19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib20","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.ijid.2011.10.004","article-title":"The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review","volume":"16","author":"Garbati","year":"2012","journal-title":"Int J Infect Dis"},{"key":"2026031105194334400_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijid.2014.07.007","article-title":"Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis","volume":"28","author":"Panackal","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2026031105194334400_bib22","article-title":"Combination antifungals for primary treatment of invasive aspergillosis (IA): do they work?","volume-title":"44th Interscience Conference on Antimicrobial Agents and Chemotherapy.","author":"Munoz","year":"2004"},{"key":"2026031105194334400_bib23","volume-title":"Combination antifungal therapy as primary therapy for invasive aspergillosis","author":"Waala","year":"2009"},{"key":"2026031105194334400_bib24","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib25","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/AAC.01141-13","article-title":"In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole","volume":"57","author":"Gregson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105194334400_bib26","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026031105194334400_bib27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/myc.12830","article-title":"Mixed mold pulmonary infections in haematological cancer patients in a tertiary care cancer centre","volume":"61","author":"Magira","year":"2018","journal-title":"Mycoses"},{"key":"2026031105194334400_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2026031105194334400_bib29","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1086\/375420","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin","volume":"187","author":"Petraitis","year":"2003","journal-title":"J Infect Dis"},{"key":"2026031105194334400_bib30","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1128\/AAC.01111-12","article-title":"Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis","volume":"56","author":"Jeans","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105194334400_bib31","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.jiph.2023.09.016","article-title":"Characteristics and outcomes for pulmonary aspergillosis in critically ill patients without influenza: a 3-year retrospective study","volume":"16","author":"Chao","year":"2023","journal-title":"J Infect Public Health"},{"key":"2026031105194334400_bib32","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2026031105194334400_bib33","doi-asserted-by":"crossref","first-page":"e02240-17","DOI":"10.1128\/AAC.02240-17","article-title":"Detection of TR(34)\/L98H CYP51A mutation through passive surveillance for azole-resistant Aspergillus fumigatus in the United States from 2015 to 2017","volume":"62","author":"Berkow","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105194334400_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12281-023-00459-z","article-title":"Invasive aspergillosis and the impact of azole-resistance","volume":"17","author":"Bosetti","year":"2023","journal-title":"Curr Fungal Infect Rep"},{"key":"2026031105194334400_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21-22","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2026031105194334400_bib36","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24 Suppl 1","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026031105194334400_bib37","first-page":"1609","article-title":"Multicenter registry of patients receiving systemic mold-active triazoles for the management of invasive fungal infections","volume":"11","author":"Ostrosky-Zeichner","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2026031105194334400_bib38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11046-023-00727-z","article-title":"Treatment of invasive aspergillosis: how it\u2019s going, where it\u2019s heading","volume":"188","author":"Boyer","year":"2023","journal-title":"Mycopathologia"},{"key":"2026031105194334400_bib39","doi-asserted-by":"crossref","first-page":"e0038022","DOI":"10.1128\/aac.00380-22","article-title":"The combination treatment of fosmanogepix and liposomal amphotericin B is superior to monotherapy in treating experimental invasive mold infections","volume":"66","author":"Gebremariam","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105194334400_bib40","doi-asserted-by":"crossref","first-page":"e02429-19","DOI":"10.1128\/AAC.02429-19","article-title":"Combination therapy with ibrexafungerp (formerly SCY-078), a first-in-class triterpenoid inhibitor of (1\u2013&gt;3)-\u03b2-d-glucan synthesis, and isavuconazole for treatment of experimental invasive pulmonary aspergillosis","volume":"64","author":"Petraitis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105194334400_bib41","doi-asserted-by":"crossref","first-page":"e00129-19","DOI":"10.1128\/AAC.00129-19","article-title":"Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease","volume":"63","author":"Seyedmousavi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105194334400_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrmicro2711","article-title":"Candida albicans morphogenesis and host defence: discriminating invasion from colonization","volume":"10","author":"Gow","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"2026031105194334400_bib43","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","author":"Kullberg","year":"2015","journal-title":"N Engl J Med"},{"key":"2026031105194334400_bib44","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/cid\/cit006","article-title":"Finding the \u201cmissing 50%\u201d of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care","volume":"56","author":"Clancy","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","article-title":"Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project","volume":"23","author":"Bassetti","year":"2019","journal-title":"Crit Care"},{"key":"2026031105194334400_bib46","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/CCM.0b013e318206c1ca","article-title":"Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study","volume":"39","author":"Kett","year":"2011","journal-title":"Crit Care Med"},{"key":"2026031105194334400_bib47","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2026031105194334400_bib48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1439-0507.2011.02044.x","article-title":"Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008)","volume":"55","author":"Tortorano","year":"2012","journal-title":"Mycoses"},{"key":"2026031105194334400_bib49","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s15010-013-0432-0","article-title":"Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project)","volume":"41","author":"Montagna","year":"2013","journal-title":"Infection"},{"key":"2026031105194334400_bib50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jinf.2017.03.011","article-title":"ICU-acquired candidaemia in France: epidemiology and temporal trends, 2004-2013\u2014a study from the REA-RAISIN network","volume":"75","author":"Baldesi","year":"2017","journal-title":"J Infect"},{"key":"2026031105194334400_bib51","doi-asserted-by":"crossref","first-page":"e7868","DOI":"10.5867\/medwave.2020.03.7867","article-title":"Evidence synthesis relevant to COVID-19: a protocol for multiple systematic reviews and overviews of systematic reviews","volume":"20","author":"Rada","year":"2020","journal-title":"Medwave"},{"key":"2026031105194334400_bib52","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00134-020-06240-x","article-title":"Invasive candidiasis in critical care: challenges and future directions","volume":"46","author":"Logan","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026031105194334400_bib53","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1128\/JCM.03239-14","article-title":"Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol","volume":"53","author":"Lau","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2026031105194334400_bib54","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijid.2020.10.092","article-title":"Candida colonization as a predictor of invasive candidiasis in non-neutropenic ICU patients with sepsis: a systematic review and meta-analysis","volume":"102","author":"Alenazy","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2026031105194334400_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17030","article-title":"Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRE) Study","volume":"17","author":"Harrison","year":"2013","journal-title":"Health Technol Assess"},{"key":"2026031105194334400_bib56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18 Suppl 7","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026031105194334400_bib57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00000658-200104000-00010","article-title":"Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients","volume":"233","author":"Pelz","year":"2001","journal-title":"Ann Surg"},{"key":"2026031105194334400_bib58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7326\/0003-4819-149-2-200807150-00004","article-title":"Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial","volume":"149","author":"Schuster","year":"2008","journal-title":"Ann Intern Med"},{"key":"2026031105194334400_bib59","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/cid\/ciu074","article-title":"MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting","volume":"58","author":"Ostrosky-Zeichner","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib60","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/cid\/civ707","article-title":"A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections","volume":"61","author":"Knitsch","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib61","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.2016.14655","article-title":"Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial","volume":"316","author":"Timsit","year":"2016","journal-title":"JAMA"},{"key":"2026031105194334400_bib62","doi-asserted-by":"crossref","first-page":"e00620-17","DOI":"10.1128\/AAC.00620-17","article-title":"Choosing optimal antifungal agents to prevent fungal infections in nonneutropenic critically ill patients: trial sequential analysis, network meta-analysis, and pharmacoeconomic analysis","volume":"61","author":"Wang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105194334400_bib63","first-page":"CD004920","article-title":"Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients","volume":"2016","author":"Cortegiani","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026031105194334400_bib64","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1097\/CCM.0000000000002698","article-title":"Antifungal prevention of systemic candidiasis in immunocompetent ICU adults: systematic review and meta-analysis of clinical trials","volume":"45","author":"Dupont","year":"2017","journal-title":"Crit Care Med"},{"key":"2026031105194334400_bib65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00019048-200009040-00006","article-title":"Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial","volume":"9","author":"Ables","year":"2000","journal-title":"Infect Dis Clin Pract"},{"key":"2026031105194334400_bib66","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1007\/s00134-002-1540-y","article-title":"Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination","volume":"28","author":"Garbino","year":"2002","journal-title":"Intensive Care Med"},{"key":"2026031105194334400_bib67","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00134-014-3352-2","article-title":"Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study)","volume":"40","author":"Albert","year":"2014","journal-title":"Intensive Care Med"},{"key":"2026031105194334400_bib68","article-title":"Comparative study of micafungin (FK 463) versus placebo as prophylactic antifungal therapy in the ICU","author":"Astellas Pharma","year":"2003"},{"key":"2026031105194334400_bib69","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib70","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1128\/JCM.06112-11","article-title":"Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata","volume":"50","author":"Pfaller","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2026031105194334400_bib71","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1086\/380796","article-title":"Guidelines for treatment of candidiasis","volume":"38","author":"Pappas","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib72","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib73","doi-asserted-by":"crossref","first-page":"e1008478","DOI":"10.1371\/journal.ppat.1008478","article-title":"Adapting to survive: how Candida overcomes host-imposed constraints during human colonization","volume":"16","author":"Alves","year":"2020","journal-title":"PLoS Pathog"},{"key":"2026031105194334400_bib74","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026031105194334400_bib75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3201\/eid2301.161198","article-title":"Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002-2012","volume":"23","author":"Strollo","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2026031105194334400_bib76","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105194334400_bib77","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib78","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/cid\/cis023","article-title":"The end of an era in defining the optimal treatment of invasive candidiasis","volume":"54","author":"Clancy","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib79","doi-asserted-by":"crossref","first-page":"e42282","DOI":"10.1371\/journal.pone.0042282","article-title":"\u03b2-d-Glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study","volume":"7","author":"Hanson","year":"2012","journal-title":"PLoS One"},{"key":"2026031105194334400_bib80","doi-asserted-by":"crossref","first-page":"iv2","DOI":"10.1093\/jac\/dky050","article-title":"T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward","volume":"73","author":"Clancy","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026031105194334400_bib81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/jof2010010","article-title":"Invasive candidiasis in various patient populations: incorporating non-culture diagnostic tests into rational management strategies","volume":"2","author":"Clancy","year":"2016","journal-title":"J Fungi (Basel)"},{"key":"2026031105194334400_bib82","doi-asserted-by":"crossref","first-page":"697330","DOI":"10.3389\/fphar.2021.697330","article-title":"Adverse effects associated with currently commonly used antifungal agents: a network meta-analysis and systematic review","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026031105194334400_bib83","doi-asserted-by":"crossref","first-page":"e969","DOI":"10.1016\/S2666-5247(22)00203-8","article-title":"The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly","volume":"3","author":"Zhang","year":"2022","journal-title":"Lancet Microbe"},{"key":"2026031105194334400_bib84","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1128\/JCM.01283-12","article-title":"Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two US cities from 2008 to 2011","volume":"50","author":"Lockhart","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2026031105194334400_bib85","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026031105194334400_bib86","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13054-019-2449-y","article-title":"The global challenge of Candida auris in the intensive care unit","volume":"23","author":"Cortegiani","year":"2019","journal-title":"Crit Care"},{"key":"2026031105194334400_bib87","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/ajg.2010.497","article-title":"Intra-abdominal fungal infections complicating acute pancreatitis: a review","volume":"106","author":"Trikudanathan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2026031105194334400_bib88","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/0003-4819-131-10-199911160-00003","article-title":"Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial","volume":"131","author":"Winston","year":"1999","journal-title":"Ann Intern Med"},{"key":"2026031105194334400_bib89","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"key":"2026031105194334400_bib90","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/imj.15589","article-title":"Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021","volume":"51 Suppl 7","author":"Keighley","year":"2021","journal-title":"Intern Med J"},{"key":"2026031105194334400_bib91","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00134-019-05599-w","article-title":"ESICM\/ESCMID task force on practical management of invasive candidiasis in critically ill patients","volume":"45","author":"Martin-Loeches","year":"2019","journal-title":"Intensive Care Med"},{"key":"2026031105194334400_bib92","doi-asserted-by":"crossref","first-page":"ofaa016","DOI":"10.1093\/ofid\/ofaa016","article-title":"Hope on the horizon: novel fungal treatments in development","volume":"7","author":"Rauseo","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/1\/34\/67292526\/ajrccm_211_1_34.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/1\/34\/67292526\/ajrccm_211_1_34.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:19:58Z","timestamp":1773220798000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/211\/1\/34\/8513348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202410-2045st","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1,1]]},"assertion":[{"value":"2024-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}